Table 1.
Antimicrobial susceptibility of E. coli isolated from women according to age range.
|
< 15 |
15-45 |
46-59 |
≥ 60 |
p-value* | |||||
|---|---|---|---|---|---|---|---|---|---|
| n | % | n | % | N | % | n | % | ||
| Amikacin | 347 | 100 | 2130 | 99.6 | 1113 | 99.9 | 1769 | 99.5 | 0.255 |
| Gentamicin | 341 | 98.3 | 2037 | 95.2 | 1059 | 95.1 | 1629 | 91.7 | <0.001 |
| Amoxicillin-clavulanic acid | 305 | 87.9 | 1901 | 88.9 | 982 | 88.2 | 1518 | 85.4 | 0.011 |
| Ampicillin | 190 | 54.8 | 1203 | 56.2 | 601 | 53.9 | 924 | 52.0 | 0.068 |
| Piperacillin-tazobactan | 338 | 97.4 | 2091 | 97.8 | 1084 | 97.3 | 1703 | 95.8 | 0.005 |
| Cephalothin | 186 | 53.6 | 1155 | 54.0 | 574 | 51.5 | 855 | 48.1 | 0.003 |
| Cefepime | 339 | 97.2 | 2079 | 97.2 | 1064 | 95.5 | 1635 | 92 | <0.001 |
| Ceftriaxone | 341 | 98.3 | 2079 | 97.2 | 1062 | 95.3 | 1625 | 91.4 | <0.001 |
| Cefuroxime | 330 | 95.1 | 2009 | 93.9 | 1020 | 91.6 | 1500 | 84.4 | <0.001 |
| Nalidixic acid | 279 | 80.4 | 1684 | 78.7 | 810 | 72.7 | 1096 | 61.7 | <0.001 |
| Norfloxacin | 330 | 95.1 | 1941 | 90.7 | 941 | 84.5 | 1306 | 73.5 | <0.001 |
| Ciprofloxacin | 329 | 94.8 | 1938 | 90.6 | 940 | 84.4 | 1303 | 73.3 | <0.001 |
| Ertapenem | 347 | 100 | 2135 | 99.8 | 1106 | 99.3 | 1770 | 99.6 | 0.087 |
| Meropenem | 347 | 100 | 2136 | 99.9 | 1108 | 99.5 | 1767 | 99.4 | 0.059 |
| Nitrofurantoin | 334 | 96.3 | 2072 | 96.9 | 1082 | 97.1 | 1698 | 95.6 | 0.079 |
| SMX /TMP | 255 | 73.5 | 1573 | 73.5 | 781 | 70.1 | 1200 | 67.5 | <0.001 |
| ESBL | 07 | 2.0 | 54 | 2.5 | 47 | 4.2 | 147 | 8.3 | <0.001 |
| TOTAL | 347 | 100 | 2139 | 100 | 1114 | 100 | 1777 | 100 | |
⁎
p valor qui square test or Exact Fisher Test.
Variables with significant association: gentamicin, amoxicillin-clavulanic, piperacillin tazobactan, cephalothin, cefepime, ceftriaxone, cefuroxime, nalidixic acid, norfloxacin, ciprofloxacin, SMX/TMP.